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Abstract
Background: Fungal bloodstream infections (BSI) may be serious and are associated with drastic rise in mortality
and health care costs. Candida spp. are the predominant etiological agent of fungal sepsis. The prompt and
species-level identification of Candida may influence patient outcome and survival. The aim of this study was to
develop and evaluate the CanTub-simplex PCR assay coupled with Tm calling and subsequent high resolution
melting (HRM) analysis to barcode seven clinically relevant Candida species.
Methods: Efficiency, coefficient of correlation and the limit of reliable detection were estimated on purified
Candida EDTA-whole blood (WB) reference panels seeded with Candida albicans, Candida glabrata, Candida
parapsilosis, Candida tropicalis, Candida krusei, Candida guilliermondii, Candida dubliniensis cells in a 6-log range.
Discriminatory power was measured on EDTA-WB clinical panels on three different PCR platforms; LightCycler®96,
LightCycler® Nano, LightCycler® 2.0. Inter- and intra assay consistencies were also calculated.
Results: The limit of reliable detection proved to be 0.2–2 genomic equivalent and the method was reliable on
broad concentration ranges (106–10 CFU) providing distinctive melting peaks and characteristic HRM curves. The
diagnostic accuracy of the discrimination proved to be the best on Roche LightCycler®2.0 platform. Repeatability
was tested and proved to be % C.V.: 0.14 ± 0.06 on reference- and % C.V.: 0.14 ± 0.02 on clinical-plates accounting
for a very high accuracy. Reproducibility was % C.V.: 0.11 between reference- and % C.V.: 0.12between clinical-
panels which is highly acceptable.
Conclusion: Our assay demonstrates recent advances on Tm calling and HRM analysis for the molecular
identification of relevant Candida species. This unique, simplex PCR assay may be capable to outperform
conventional phenotypic methods by reducing time and providing accurate and reliable results directly from blood
(2 h) or from whole blood culture bottles (12–24 h).
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Background
Fungal bloodstream infections may be serious and are asso-
ciated with drastic rise in mortality and health care costs [1,
2]. Currently, with the gradually growing number of im-
munocompromised patients, we face an appreciable shift in
the spectrum of fungal infections [3, 4]. The genus Candida
corresponds to the most important cause of opportunistic
mycoses in the world [5, 6]. Despite the antifungal therapy
nosocomial Candida infections constitute a public health
problem contributing to prolonged hospitalization time,
generating enormous excess of costs for patient treatment,
and a high mortality (25–60%) especially when complicated
with septic shock [7, 8].
Candida spp. account for 70–80% of invasive fungal
BSIs representing the third most frequent (all over 8–10%)
cause of all BSIs in the intensive care unit (ICU) [9–13].
Nearly 95% of invasive candidemias are caused by Candida
albicans, Candida glabrata, Candida parapsilosis, Can-
dida tropicalis and Candida krusei [14–16]. The remaining
5% are caused by 10–12 species, such as C. guilliermondii,
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C. dubliniensis provoking superinfections due to their low
sensitivity to broad-spectrum antifungals [10, 17]. The inci-
dence of infections due to non-albicans species is continu-
ously growing [13, 17]. Candida BSIs do not present with
species specific clinical manifestations or laboratory abnor-
malities, thus the clinical course of the disease and the
outcome are comparable in patients with sepsis caused by
C. albicans and non-albicans species [12, 18].
Timely diagnosis of sepsis due to candidemia is essen-
tial for effective therapy, while delays of more than 12 h
in the administration of antifungal drugs may substan-
tially increase mortality [19–23].
The rapid and correct identification of Candida spe-
cies can narrow therapy options by preventing treatment
with potentially toxic antifungal agents, thus reducing
costs of hospitalization and improving negative patient
outcomes [24–26]. Because of the phenotypic similarities
of Candida species, the turn-around time of traditional,
culture based identification methods may take 2 to
8 days, delay adequate diagnosis and appropriate anti-
fungal treatment. In comparison the surrogate-marker
based molecular assays requiring an average of 3–4 h [27].
Nevertheless in some cases the morphological identifica-
tion of clinically relevant Candida species is hampered by
several difficulties, as is the case with the germ tube positive
C. albicans and the potentially fluconazole-resistant, cryptic
C. dubliniensis providing light green vs. dark green colonies
on CHROM agar presenting only subtle differences in col-
ony color [28, 29].
With regard to surrogate-marker based molecular
methods, the antimannan antibody (Platelia GM-enzyme
immunoassay, Bio-Rad) and 1,3-ß-D-glucan (BDG) antigen
based (Fungitell assay, Associates of Cape Cod) immuno-
logical assays have good performances and may be useful in
diagnosing of invasive fungal infections [30]. Nonetheless,
as the panfungal BDG is a major cell wall component of
Candida and other fungi, except Cryptococci and Zygomy-
cetes, it not suitable for the identification even to the genus
level [12].
Along with the growing number of annotated protein
spectra and the development of refined and standardized
methodologies of protein extraction methods, matrix assisted
laser desorption/ionization time-of-flight (MALDI-TOF)
mass spectrometry (MS) has emerged as a powerful technol-
ogy for the prompt identification of microorganisms in
clinical microbiology supporting genus-, or species-oriented
treatment [31–33].
The DNA sequencing methods, targeting the 18S rRNA
genes or ITS regions, can generate accurate species-level
identification for many microbial isolates; however these
methods are time consuming and technically demanding.
Polymerase chain reaction (PCR)-based techniques ap-
pear to be promising in terms of speed, economy, and
resolution power [34]. PCR based patient follow up were
shown to be capable to precede clinical signs of invasive
candidiasis (IC) with the range of 1 day to 4 weeks,
furthermore treatment could be initiated 3 days (range:
0–8 days) before the blood culture diagnosis was taken
[35]. There have been numerous platforms and gene
targets used for Candida spp. identification, such as
those genes encoding cytochrome P450, actin and L1A1,
and the highly variable internal transcribed spacer re-
gions; ITS1 and ITS2 in combination with the relatively
conserved regions of 18S, 5.8S or 28S nuclear rRNA
genes [36–41].
MALDI-TOF and real-time PCR applications have high
throughput, low-cost in supplies, short turnaround time.
Both tools have the advantage to identify a broad-range of
clinically relevant pathogenes with high accuracy at the
species level Though MALDI-TOF is not suitable to de-
tect a low amount of microorganisms directly from blood
and PCR techniques usually lack standardization.
The prime aim of this study is to develop and evaluate a
real-time PCR method which can identify and differentiate
among seven relevant Candida spp. with high accuracy in a
single, closed tube system, by a post-PCR Tm calling assay
coupled with a contingent high-resolution melting (HRM)
analysis. This barcoding method is a single locus based
HRM system which relies on the conserved regions of Can-
dida beta-tubulin genes permitting reliable and precise
species-specific identification of seven reference strains and
38 clinical isolates. To our knowledge, there is no other pub-
lished method which is tailored to a single domain of Can-
dida beta-tubulin genes and there is no other conventionally
available or presented simplex PCR assay.
Methods
Fungal and bacterial strains
Genomic DNA (gDNA) samples of 81 clinically relevant
fungal strains; Candida (43), aspergilli (32), Fusarium
(4), Lichtemia (1), Rhyzopus (1), Scedosporium (1) and
16 bacteria; Gram-positive (10) and Gram-negative (6)
were examined. The reference strains and clinical
isolates (Table 1) were maintained at the Department of
Microbiology, University of Szeged and at the Depart-
ment of Medical Microbiology, University of Debrecen.
To preserve the viability and purity of fungal and bacter-
ial strains they were maintained in 50% glycerol stock
solution at − 80 °C and were periodically subcultured.
DNA extraction
All genomic DNA (gDNA) extraction steps were performed
in a class II laminar-flow cabinet to avoid environmental
contamination.
Fungal gDNA extraction
Candida cultures used for the molecular identification
of the strains were grown on yeast-peptone D-glucose
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Table 1 List of the reference and clinical strains examined by CanTub-simplex PCR
DNA serial ID. Strain designation number Organism Tm °C
Yeasts Reference ATCC 10231 Candida albicans 78.77 ± 0.06
1 DMC 14134 Candida albicans 78.60 ± 0.08
2 DMC 3666 Candida albicans 78.70 ± 0.11
3 DMC 40678 Candida albicans 78.43 ± 0.16
4 SZMC 22801 Candida albicans 78.57 ± 0.12
5 SZMC 22800 Candida albicans 78.77 ± 0.02
6 SZMC 1523 Candida albicans 78.69 ± 0.05
7 SZMC 1422 Candida albicans 78.67 ± 0.11
Reference ATCC 90030 Candida glabrata 81.55 ± 0.03
8 SZMC 1353 Candida glabrata 81.44 ± 0.14
9 SZMC 1362 Candida glabrata 81.59 ± 0.12
10 SZMC 1370 Candida glabrata 81.30 ± 0.15
11 SZMC 1374 Candida glabrata 81.55 ± 0.14
Reference ATCC 22019 Candida parapsilosis 80.16 ± 0.05
12 DMC 6378 Candida parapsilosis 80.18 ± 0.10
13 DMC 6403 Candida parapsilosis 80.26 ± 0.15
14 DMC 16879 Candida parapsilosis 80.26 ± 0.02
15 SZMC 23640 Candida parapsilosis 79.91 ± 0.02
16 SZMC 8114 Candida parapsilosis 80.18 ± 0.06
17 SZMC 1593 Candida parapsilosis 80.12 ± 0.04
Reference ATCC 750 Candida tropicalis 78.47 ± 0.11
18 DMC 10776 Candida tropicalis 78.13 ± 0.16
19 DMC 2696 Candida tropicalis 78.36 ± 0.02
20 DMC 3403 Candida tropicalis 78.25 ± 0.14
21 SZMC 1351 Candida tropicalis 78.20 ± 0.10
22 SZMC 1364 Candida tropicalis 78.17 ± 0.07
23 SZMC 1366 Candida tropicalis 78.33 ± 0.06
24 SZMC 1368 Candida tropicalis 78.13 ± 0.11
Reference ATCC 6258 Candida krusei 79.31 ± 0.05
25 DMC 26513 Candida krusei 79.27 ± 0.01
26 DMC 23697 Candida krusei 79.34 ± 0.06
27 DMC 22910 Candida krusei 79.39 ± 0.07
28 SZMC 1352 Candida krusei 79.20 ± 0.03
29 SZMC 1414 Candida krusei 79.32 ± 0.05
30 SZMC 1447 Candida krusei 79.24 ± 0.12
31 SZMC 1450 Candida guilliermondii 81.09 ± 0.10
32 SZMC 0808 Candida guilliermondii 81.01 ± 0.06
33 SZMC 1536 Candida guilliermondii 81.08 ± 0.12
34 SZMC 1357 Candida guilliermondii 80.84 ± 0.11
35 SZMC 1469 Candida dubliniensis 77.91 ± 0.05
36 SZMC 1470 Candida dubliniensis 77.75 ± 0.01
37 SZMC 1471 Candida dubliniensis 77.62 ± 0.03
38 SZMC 1472 Candida dubliniensis 77.62 ± 0.08
Moulds Reference FGSC A1156 Aspergillus terreus –
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Table 1 List of the reference and clinical strains examined by CanTub-simplex PCR (Continued)
DNA serial ID. Strain designation number Organism Tm °C
39 SZMC 22546 Aspergillus terreus –
40 SZMC 22547 Aspergillus terreus –
41 SZMC 22548 Aspergillus terreus –
42 SZMC 22549 Aspergillus terreus –
Reference CBS 101355/AF 293 Aspergillus fumigatus –
43 SZMC 2504 Aspergillus fumigatus –
44 SZMC 2486 Aspergillus fumigatus –
45 SZMC 22550 Aspergillus fumigatus –
46 SZMC 22551 Aspergillus fumigatus –
47 SZMC 22552 Aspergillus fumigatus –
48 SZMC 22553 Aspergillus fumigatus –
49 SZMC 22554 Aspergillus fumigatus –
Reference CBS 117885 Aspergillus lentulus –
50 SZMC 3123 Aspergillus lentulus –
51 SZMC 20911 Aspergillus lentulus –
Reference NRRL 11611 Aspergillus flavus 86.36
52 SZMC 22583 Aspergillus flavus –
53 SZMC 22582 Aspergillus flavus –
54 SZMC 22581 Aspergillus flavus 86.61
55 SZMC 22580 Aspergillus flavus 86.34
56 SZMC 22578 Aspergillus flavus 86.39
57 SZMC 22577 Aspergillus flavus –
58 SZMC 22575 Aspergillus flavus 86.38
Reference CBS 113.46 Aspergillus niger 86.57
59 SZMC 3119 Aspergillus niger 86.75
60 SZMC 3108 Aspergillus niger –
Reference CBS 134.48 Aspergillus tubingensis –
61 SZMC 3127 Aspergillus tubingensis –
62 SZMC 2040 Aspergillus udagawae –
63 SZMC 2041 Aspergillus udagawae –
64 SZMC 21694 Aspergillus viridinutans –
65 SZMC 13F Fusarium sacchari –
66 SZMC 90/11 Fusarium napiforme –
67 SZMC 173/11 Fusarium delphinoides –
68 SZMC 394/11 Fusarium oxisporum –
69 SZMC FSU9682 Lichtemia corymbifera –
70 SZMC RH59 Rhizopus oryzae 43.13, 77.38
71 SZMC Sce Scedosporium aurantiacum 37.54, 75.73
Gram-positive bacteria Reference ATCC 25923 Staphylococcus aureus –
72 SZMC 14529 Staphylococcus aureus –
73 SZMC 14530 Staphylococcus aureus –
74 SZMC 14532 Staphylococcus aureus –
Reference ATCC 29213 Staphylococcus aureus –
Reference ATCC 43300 Staphylococcus aureus –
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(YPD) for 2 days, and DNA was extracted using the
Masterpure™ Yeast DNA Purification Kit (Epicentre Bio-
technol., Madison, USA) per the manufacturer’s instruc-
tions [42]. Mould reference strains (Aspergillus only)
and clinical isolates (Aspergillus, Fusarium, Lichtemia,
Rhyzopus, Scedosporium) were cultivated on standard
minimal nitrate medium [43]. DNA extractions were
carried out at the University of Debrecen (Department
of Biotechnology and Microbiology). gDNA was isolated
from liquid cultures grown in minimal medium at 37 °C
(A. fumigatus, A. niger), 25 °C (A. terreus, A. lentulus, A.
flavus) and 30 °C (A. welwitschiae) at 220 rpm for 18 h.
The mycelium was disrupted by using Roche MagNa
Lyser (Roche Diagnostics, Risch-Rotkreuz, Switzerland)
and gDNA was isolated using the Genomic DNA Purifi-
cation Kit (Thermo Scientific, Maryland, USA) per the
manufacturer’s instructions.
Bacterial gDNA extraction
The bacterial strains were grown on Müller-Hinton agar
base under aerobic conditions. DNA was extracted using
the E.Z.N.A.® Bacterial DNA Kit (Omega Biotech, Norcross,
Georgia, USA) per the manufacturer’s instructions. Briefly,
for suspension cultures one millilitre of log phase culture
with approximately 108 bacterial cells was used and cells
were pelleted by centrifugation. Gram-positive bacterial cell
walls were lysed by lysozyme solution with 20 mg ml− 1 en-
zyme in 20 mM Tris HCL, pH 8.0 2 mM EDTA, 1.2%
TritonX100).
DNA concentrations and purity were measured using
NanoDrop-1000 spectrophotometer (NanoDrop Technolo-
gies, Inc., North Carolina, USA).
CanTub-simplex PCR
Annotated sequences of the Candida beta-tubulin genes
were extracted from the EMBL/GeneBank databases to
make multiple alignments using Clustal Omega. Available
Candida beta-tubulin sequences were aligned surveying
potential sequence deviations within species. When de-
signing primers, we screened for melting domains cover-
ing enough mismatches to enable proper discrimination
among the tested strains but comprising 30–40 nucleotide
long conserved nucleotides on flanking regions for the
very specific hybridization of primers and avoiding
cross-reactions with gDNA of other BSI causing fungal,
bacterial strains and with the human genomic DNA.
The CanTub forward primer is 37 bp long(5’-CTAA
AATCAGAGAAGAATTCCCCTGATAGAATGATGGC-3′),
GC content 37.8%, Tm 73.2 °C and the CanTub re-
verse primer is 43 bp long (5’-CAATTGACCTGGGA
TAACGTAAAGAAGTAGTAACACCAGACAT-3′),
GC content 38%, Tm 74.2 °C.
Setting the optimal CanTub-simplex PCR conditions
Temperature gradient assay was performed from 55 to
72 °C for assessing the performance of the primer pair
during amplification with a temperature gradient program
using the LightCycler® 96 thermal cycler Instrument
(Roche Applied Science, Penzberg, Germany). The MgCl2
optimization was performed by adding different amounts
of MgCl2 within the concentration range 1 to 3.5 mM.
The primer optimization assay was performed using 0.2,
0.4, 0.6 μM of the forward and reverse primers.
Verification of the CanTub-simplex amplicons via
conventional PCR
In order to monitor the accumulation of aspecific amplicons
in the CanTub-simplex PCR, primers were tested with
20 ng gDNA of five Candida reference strains (C. albicans
ATCC 10231, C. glabrata ATCC 90030, C. parapsilosis
ATCC 22019, C. tropicalis ATCC 750, C. krusei ATCC
6258), and two clinical isolates (C. guilliermondii SZMC
Table 1 List of the reference and clinical strains examined by CanTub-simplex PCR (Continued)
DNA serial ID. Strain designation number Organism Tm °C
75 SZMC 14531 Staphylococcus epidermidis –
Reference ATCC 29212 Enterococcus faecalis –
Reference ATCC 8043 Enterococcus hirae –
76 SZMC 14538 Enterococcus faecalis –
Gram-negative bacteria Reference ATCC 13048 Enterobacter aerogenes –
77 SZMC 6222E Enterobacter gergoviae –
78 SZMC 6223 Enterobacter gergoviae –
79 SZMC 6224 Enterobacter gergoviae –
80 SZMC 21890 Enterobacter cloacea –
81 SZMC 21892 Enterobacter cloacea –
Clinical isolates are from the Szeged Microbiology Collection (SZMC) and from the Debrecen Microbiology Collection (DMC). Reference strains are from American
Stock Centre (ATCC), Centraalbureau voor Schimmelcultures, Fungal and Yeast Cultures (CBS), Northern Regional Research Laboratories (NRRL), Fungal Genetics
Stock Centre (FGSC)
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1536 and C. dubliniensis SZMC 1470 depicted by ID33 and
ID36 in Table 1). The thermocycling reactions were con-
ducted in a Roche LightCycler®Nano instrument (P2).
200 ng of the yielded CanTub PCR amplicons were electro-
phoresed on 2% TBE-agarose gel stained with
ethidium-bromide to investigate aspecific PCR increments.
Real time PCR platforms
Real-time PCR assays were conducted on three different
PCR platforms (P1, P2, P3). (P1) LightCycler® 96 thermal cy-
cler, (P2) LightCycler® Nano and (P3) LightCycler® 2.0 Instru-
ments (Roche Diagnostics, Risch-Rotkreuz, Switzerland)
were used with the LightCycler 480 High-Resolution Melting
Master (Roche Applied Science, Penzberg, Germany) (P1)
10 μl reaction volumes consisted of 5 μl 2× LightCycler 480
High Resolution Melting Master, 0.5 μl of each primer
(0.4 μM), 1 μl MgCl2 (2 mM) and 3 μl template DNA. The
thermocycling reactions were conducted in a LightCycler
480 Multiwell Plate, (white). (P2), (P3) 20 μl reaction vol-
umes consisted of 10 μl 2× LightCycler 480 High Resolution
Melting Master, 0.5 μl of each primer (0.4 μM), 5 μl PCR
grade water, 1 μl MgCl2 (2 mM) and 3 μl template DNA.
The thermocycling reactions were conducted in LightCycler®
8-Tube Strips (P2) and in 20 μl glass capillaries (P3). The
real-time PCR runs always included at least two controls of
reaction mix without DNA (non-template control - NTC).
Temperature parameters were set as follows: an initial de-
naturing step of 95 °C for 10 min followed by 50 cycles of
denaturation at 95 °C for 10 s, annealing at 60 °C for 10 s
and extension at 72 °C for 10 s. Fluorescent data were col-
lected in the ResolightDye channel (470/514 nm).
Melting temperature calculation and HRM protocols
The accumulation of the Candida species descriptive ampli-
cons was monitored via melting temperature calculation and
HRM analysis on three real-time PCR platforms.
(P1), (P2) Following the completion of real-time PCR,
the products were denatured at 95 °C for 15 s (4.4 °C s− 1),
and then renatured at 40 °C for 15 s (1 °C s− 1) to form
DNA duplexes. HRM analysis was performed by increasing
the temperatures from 45 to 97 °C (0.2 °C s− 1) recording
changes in fluorescence (-dF/dT) and plotting against
changes in temperature. The HRM profiles were then ana-
lyzed using the LightCycler®96 HRM analysis and the Light-
Cycler® Nano Software thus highly dense measurement
points were taken during the high resolution melting stage
resulting in species descriptive HRM melting curves.
(P3) HRM analysis was not performed with the LC 2.0
software due to the lack of this option. For Tm analysis
melting temperature measurement was set from 45 to
97 °C (0.05 °C s− 1). Melting peaks were analyzed by the
LightCycler®2.0 Software.
Cross reactivity
Possible cross reactions of the CanTub-HRM assay
were tested with approximately 20–25 ng purified
(OD260/2801.82–1.97) gDNA of human placenta (Sigma Al-
drich, Missouri, USA) and the gDNA samples of 32 asper-
gilli; 6 reference strains (Aspergillus terreus FGSC A1156,
A. fumigatus Af293, A. lentulus CBS117885, A. flavus
NRRL11611, A. niger CBS 113.46, A. tubingensis CBS
134.48), further 26 gDNA of Aspergillus (ID39–64), Fusar-
ium (ID65–68), Lichtemia corymbifera (ID69), Rhyzopus
oryzae (ID70), Scedosporium aurantiacum (ID71) clinical
isolates, finally with the gDNA of 10 Gram-positive bac-
teria; 5 reference strains (Staphylococcus aureus ATCC
25923, 29,213, 43,300, Enterococcus faecalis ATCC 29212,
Enterococcus hirae ATCC 8043), 5 Gram-positive clinical
isolates (ID72–76) and with 6 Gram-negative bacteria; En-
terobacter aerogenes ATCC13048 reference strain and five
Gram-negative clinical isolates (ID77–81) in Table 1.
Verification of the CanTub-simplex assay on EDTA-whole
blood panels
Obtaining of EDTA-WB samples for spike in controls
Working with WB samples from healthy volunteers was ap-
proved by the local ethics committee, MK-JA/50/0096–01/
2017. Participants agreed to take part in this study. EDTA
whole blood samples obtained from healthy volunteers
were pooled and screened for Candida contamination prior
to use as extraction negative controls (ENC).
Candida EDTA-WB reference panels
To obtain Candida reference panels in a 6-log range (Can-
dida albicans ATCC 10231; ref-panel_1, C. glabrata ATCC
90030; ref-panel_2, C. parapsilosis ATCC 22019; ref-panel_3,
C. tropicalis ATCC 750; ref-panel_4, C. krusei ATCC 6258;
ref-panel_5, C. guilliermondii SZMC1536; ref-panel_6, C.
dubliniensis SZMC 1470; ref-panel_7), 990 μl of EDTA-WB
samples were seeded with 10 μl of log-phase culture suspen-
sions at a cell density of 108–102 CFU in one millilitre of
yeast suspensions. Following DNA purification the sample
extracts contained 2 × 105 (106 CFU/1 ml WB) – 0.2
(10 CFU/1 ml WB) GE in 3 μl of PCR template.
Candida EDTA-WB clinical panels
EDTA-WB samples at a cell density of 104 CFU/ml Candida
strains (ID1–38) were used to perform seven Candida clin-
ical panels (ID1–7; clin-panel_1, ID8–11; clin-panel_2,
ID12–17; clin-panel_3, ID18–24; clin-panel_4, ID25–30;
clin-panel_5, ID31–34; clin-panel_6, ID35–38; clin-panel_7).
Following DNA purification the sample extracts contained
200 GE in 3 μl of PCR template.
DNA purification from EDTA-WB samples
DNA purification steps were performed in a class II laminar
air-flow cabinet to avoid environmental contamination.
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Spiked EDTA-WB samples were disrupted (2000 rpm,
1 min) by Roche MagNa Lyser (Roche Diagnostics,
Risch-Rotkreuz, Switzerland), and DNA was extracted along
with the ENCs using the High Pure Viral Nucleic Acid Large
Volume Kit (Roche Applied Science) according to manufac-
turer’s instructions. To obtain technical duplicates every
sample extractions were performed in parallel. The elution
volumes were adjusted to 15 μl and pooled.
PCR efficiency and the limit of reliable detection (LoRD)
Amplification reactions were carried out on three differ-
ent PCR platforms; P1, P2, P3. Duplicate PCRs were per-
formed at every dilution of the Candida EDTA-WB
reference panel extracts. Quantification cycle (Cq) values
were subtracted and melting curves were analyzed to es-
timate the lowest template DNA concentration by which
the appropriate, species descriptive melting peaks were
interpretable (LoRD). To study the correlation between
the Cq-s and the genomic load standard curves were
obtained by plotting Cq values against the log of cell
number; 106–10 CFU/1 ml WB which is equivalent to
2 × 105–0.2 GE/PCR. Mean Cq data were calculated and
standard curves were built where these plots determined
the linear dynamic ranges. Efficiency was calculated per
the following formula, E = (10–1/slope) than was con-
verted to percentage efficiency by using the formula, E%
= (E-1) × 100 [44]. Amplification efficiency, (correlation
coefficient; R2) was also calculated.
In-house quality assessment
PCRs were conducted on P1 and Tm data were subtracted.
Determining the repeatability
To estimate repeatability intra-assay consistency was cal-
culated. To calculate the coefficient of variation (% C.V.)
of the CanTub-simplex PCR within the three PCR plates
(ref-plate_1, _2, _3) of the seven Candida reference
panel extracts (ref-panel_1-_7) and within the four PCR
plates (clin-plate_1, _2, _3, _4) of the seven Candida
clinical panel extracts (clin-panel_1-_7) standard devi-
ation (±SD) of duplicate Tm mean data were taken, div-
iding these numbers by the mean of the Tm values and
multiplying them by 100 [see Additional file 1]. Finally,
the grand mean of the sample coefficient of variations
(average % C.V.-s) of the three plates was taken defining
the plate % C.V. values. When the intra-assay % C.V. is
below 10% the method under investigation has high
precision.
Determining the reproducibility
To estimate the precision of the CanTub-simplex PCR as
regards discrimination of the relevant Candida species
and to confirm that results generated are consistent over
time inter-assay consistency (plate-to-plate variation) was
estimated between the PCR plates on three distinct days
with the seven Candida reference panel extracts and with
the sample extracts of the seven Candida clinical panels
[see Additional file 2]. In the case of the Candida panels
duplicate PCRs were performed on every sample isolate.
Tm data were subtracted than mean Tm (°C) with standard
deviations (±SD) were calculated. When analyzing
Candida clinical panels, duplicate Tm means of adherent
clinical strains of the different species were assembled and
overall mean was calculated. Plate coefficient of variations (%
C.V.) was calculated. Finally, grand mean of the sample coef-
ficient of variations (average % C.V.-s) was taken. Inter-assay
% C.V. values less than 15% are generally acceptable.
Results
In silico assessment of the CanTub forward and CanTub
reverse primers
Based on the sequence alignment data we presumed that
the amplicons generated by CanTub-simplex primers
will display enough sequence divergence between closely
related Candida species but at the same time may be
conserved enough barcoding the different clinical isolates
within species. Primer matches with annotated beta-tubulin
genes from C. albicans, C. tropicalis, C. dubliniensis and C.
glabrata are indicated in [see Additional file 3] with the sizes
of the amplicons.
Optimal reaction conditions with the CanTub-simplex PCR
Optimal reaction conditions were determined as described
in the methods section. 0.4 μM primers-, 2 mM MgCl2-con-
centrations and annealing at 60 °C proved to be optimal.
The size of the amplified CanTub-simplex PCR bands were
verified on five Candida reference strains and on two clinical
isolates. All the amplified CanTub-simplex PCR fragments
are smaller than 300 bp in size and we did not experience
any aspecific PCR increments (data not shown).
Cross reactivity
No cross-amplification was detected with the human gen-
omic DNA and with the Gram-negative and Gram-positive
bacteria. Furthermore, no cross-amplification was observed
with A. terreus, A. lentulus, A. tubingensis, A. viridinutans
and A. udagawae strains. Mild cross reaction was detected
with the A. fumigatus, A. flavus and A. niger providing Tm
peaks at 86.35 ± 0.16 °C and displaying inconclusive HRM
curves and peaks. Moderate false positivity with plain, incon-
sistent peaks were detected in the case of Rhyzopus oryzae
(77.38 °C), Scedosporium aurantiacum (75.73 °C) generating
cycle threshold (Cq) values greater than Cq > 42 (data not
shown).
Analytical sensitivity
LoRD of the simplex CanTub-PCR assay was estimated on
Candida EDTA-WB standard panel extracts containing
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serially diluted Candida gDNA in a 6-log range. Linear dy-
namic ranges were assessed on P1, P2, and P3 with PCR effi-
ciency (E) and coefficient of correlation (R2) were also
estimated using the standard curve data (Fig. 1). The analyt-
ical sensitivity with the lowest concentration of template
DNA where reliable identifications with conclusive melting
peaks and HRM curves were attainable in the case of at least
one technical duplicate proved to be 0.2 GE/PCR (10 cells/
1 ml WB) on all panels and on all platforms except the C.
parapsilosis reference panel on P1 and P3, where LoRD
proved to be 2 GE/PCR (100 cells/1 ml WB) only. On P2
the LoRD was 2 GE/PCR also for C. parapsilosis, C. dubli-
niensis and C. guilliermondii reference panels.
Maximum discriminatory property was achieved by
defining seven melting clusters on three real-time
platforms
CanTub-simplex assay targeting the beta-tubulin genes
proved to be accurate and reliable for specific identification
of seven Candida species. Thirty eight clinical isolates
phenotypically identified as Candida species were subse-
quently tested in a blinded manner and barcoded due to
comparing the melting data to those of the reference strains.
Normalized melting curves (Fig. 2/a) with the difference
plot (Fig. 2/b) are shown by using saturating concentrations
of a fluorescent double stranded DNA intercalating Reso-
Light® dye. HRM analyses were performed on Candida
EDTA-WB clinical panels and on platform P1.
Whisker plots show the distribution of the Tm values
when testing the 38 Candida clinical strains on four sep-
arate plates. For every dataset, the median, minimum,
maximum Tm values along with the 25th and 75th per-
centile are also shown in Fig. 3. Based on the distribu-
tion of the melting temperature data of the Candida
strains tested, we created seven melting clusters for the
reliable species level identification on P1-P3 C. dubli-
niensis cluster_1 Tm with 95% CI: 77.58 ± 0.32 °C (P1),
78.39 ± 0.22 °C (P2), 76.45 ± 0.37 °C (P3). C. tropicalis
cluster_2 Tm with 95% CI: 77.96 ± 0.2 °C (P1), 78.77 ±
0.21 °C (P2), 77.09 ± 0.41 °C (P3). C. albicans cluster_3
Tm with 95% CI: 78.64 ± 0.18 °C (P1), 79.16 ± 0.14 °C
(P2), 77.61 ± 0.15 °C (P3). C. krusei cluster_4 Tm with
95% CI: 79.17 ± 0.26 °C (P1), 78.64 ± 0.18 °C (P2), 78.17
± 0.24 °C (P3). C. parapsilosis cluster_5 Tm with 95%
CI: with 95% CI: 79.92 ± 0.37 °C (P1), 80.08 ± 0.3 °C (P2),
78.65 ± 0.39 °C (P3). C. guilliermondii cluster_6 Tm with
95% CI: 80.98 ± 0.3 °C (P1), 81.19 ± 0.3 °C (P2), 79.76 ±
0.18 °C (P3). C. glabrata cluster_7 Tm with 95% CI:
81.3 ± 0.31 °C (P1), 81.6 ± 0.32 °C (P2), 82.02 ± 0.32 °C
(P3).Using these melting clusters for PCR typifying of
Fig. 1 Regression lines of CanTub-simplex PCR on P1-P3 platforms. The limit of reliable detection (LoRD) was evaluated on seven, purified Candida EDTA-
WB reference panels of the Candida albicans (ATCC 10231), Candida glabrata (ATCC 90030), Candida parapsilosis (ATCC 22019), Candida tropicalis (ATCC
750), Candida krusei (ATCC 6258) type strains and the Candida guilliermondii (SZMC 1536) and Candida dubliniensis (SZMC 1470) clinical isolates. Y-intercept,
slope, PCR reaction efficiency (E%), error (±), coefficient of correlation (R2), and limit of reliable detection (LoD) measured in 20 μl PCR reactions are shown
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unknown Candida strains there is no need for using
standards as reference controls.
Repeatability and reproducibility
We estimated the intra-, and inter-assay consistency of the
CanTub-simplex PCR on Candida EDTA-WB reference-
[see Additional file 1] and on Candida EDTA-WB clinical
panels [see Additional file 2]. For measuring the precision
of the assay average coefficient of variation was calculated
for the technical duplicate Tm values measured on P1
where intra-assay % C. V. proved to be 0.14 (ref. plate_1),
0.19 (ref. plate_2) and 0.08 (ref. plate_3) on Candida
EDTA-WB reference plates and 0.14 (clin. plate_1), 0.12
(clin. plate_2), 0.10 (clin. plate_3), 0.13 (clin. plate_4) on
Candida EDTA-WB clinical plates accounting for a very
high accuracy of the CanTub-simplex PCR. Plate-to-plate
consistency was also assessed for the assay between
the three Candida EDTA-WB reference plates and the
four Candida EDTA-WB clinical panels. Reproducibil-
ity was measured and sample coefficient of variations
(grand % C.V.-s) between the three reference and four
clinical plates were taken, where inter-assay proved to
be 0.11between standard [see Additional file 1] and
0.12between clinical panels [see Additional file 2]
which is highly acceptable.
Discussion
With the continuously growing population of immunocom-
promised patients, the number of invasive fungal infections
has increased significantly over the past decades [1–4].
Among all, Candida species are the most prevalent etiology
of sepsis and septic shock in critically ill patient groups
representing a significant health challenge with increasing
medical and economic importance [7–9]. Concern is rising
about the growing incidence of non-albicans infections and
the emergence of their various intrinsic or acquired
resistances. Over the last two decades, the occurrence of
non-albicans species have emerged [12, 13, 17, 18, 26]. More
than 98% of candidemia cases are caused by C. albicans, C.
a
b
Fig. 2 Discriminatory property of the CanTub-simplex PCR. Species level identification was achieved by using CanTub-simplex PCR primer pair to
accurately identify Candida species based on HRM analysis (P1) by using the LightCycler®96 HRM analysis Software (Roche Diagnostics, Risch-
Rotkreuz, Switzerland). a Representation of the normalized CanTub-simplex PCR melting curves. Each colour represents a different species:
Candida albicans (blue) ID1–7; Candida glabrata (red) ID8–11; Candida parapsilosis (yellow) ID12–17; Candida tropicalis (orange) ID18–24; Candida
krusei (green) ID25–30; Candida guilliermondii (brown) ID31–34; Candida dubliniensis (pink) ID35–38. b Representation of the normalized difference
plots. Normalized difference plots against Candida albicans
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glabrata, C. parapsilosis, C. tropicalis, C. krusei, including
further species such as C. dubliniensis, and C. guillermondii
[14–16].
Identification of Candida species is important due to
the differences in the antifungal susceptibility profile as-
sociated with species and because of the limitation of
the phenotypic identification [10–17].
The traditional culture based morphological (colony
and microscopic morphology), and/or biochemical (such
as sugar assimilation and fermentation tests) identifica-
tion methods of the Candida species are laborious, re-
quiring a high level of skills and expertise of clinical
mycologists and a long period of time, limiting patient
care [27, 28]. Morphological identification of certain spe-
cies remains problematic due to the high degree of pheno-
typic similarities between C. albicans versus C. tropicalis
and C. dubliniensis out of which the latter species can ac-
quire stable fluconazole resistance rapidly [28].
Fig. 3 Whisker plots of the Candida species descriptive clusters. Whisker plots representing the discriminatory power of the CanTub-simplex PCR
were created based on the digitalized melting temperature (Tm) data representing the seven melting clusters (pink cluster_1 for Candida
dubliniensis, orange cluster_2 for Candida tropicalis, blue cluster_3 for Candida albicans, green cluster_4 for Candida krusei, yellow cluster_5 for
Candida parapsilosis, brown cluster_6 for Candida guilliermondii, red cluster_7 for Candida glabrata) for the discrimination of the Candida species.
Melting peaks were subtracted from the analysis of purified the Candida EDTA-WB clinical panel extracts (P1-P3). Tm data of adherent clinical
strains of the different species were assembled and data were grouped. Whisker plots were constructed for each data group showing the range
of obtained temperatures of melting (Tm); the minimum, the median, and the maximum Tm values with 25th and 75th percentiles
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There is an increasing demand for innovative sensitive,
rapid and non-invasive methods for identification of
Candida species at an early stage of the disease.
Tm calling assays especially when coupled with HRM
analysis has been introduced for scanning genotypes and
for the rapid discrimination between DNA sequences
based on their variant high resolution melting profiles
without the use of fluorescent labeled probes. Although
HRM based methods do not have the resolving power
that many sequencing techniques have and are not as
sensitive as the TaqMan probe based systems, they be-
came more and more attractive to molecular diagnostic
laboratories. Our recent data also support that applica-
tions resting on HRM analyses may be ideally suited for
identifying or ruling out certain fungal and bacterial
pathogens in clinical diagnostic workflow.
In 2007 Carvalho and colleagues developed and tested
on 231 Candida isolates a sensitive (2.15 ± 0.25 CFU/
1 ml), multiplex PCR based method by using yeast specific
(ITS1, ITS2) universal and species-specific (18S, 28S)
primers allowing the barcoding of eight relevant Candida
strains (C. albicans, C. glabrata, C. parapsilosis, C. tropica-
lis, C. krusei, C. guilliermondii, C. lusitaniae and C. dubli-
niensis) at the species level taking the advantage of the
presence of high-copy number of rRNA genes due to the
presence of characteristic PCR amplified band patterns
[36]. The only drawback of this method is that barcoding
of unknown yeasts require running eight simultaneous
PCR assays.
The CanTub-simplex PCR assay described here relies
on a single primer pair targeting specific regions of Can-
dida beta-tubulin genes.
The assay provides reliable nucleic acid based testing
for proper identification of seven relevant Candida spe-
cies by defining the species-specific melting domains
and/or the shape of the derivative melting curves on the
three real-time platforms (P1-P3).
When analyzing 1 ml of WB samples infected with 106–10
Candida cells the amplification efficiency was 100% on all
reference panels (ref. panel_1 – ref. panel_7) observing effi-
cient amplification and melt curve analysis. For samples
seeded with 1 CFU sample the barcoding capacity proved to
be only 78.57%. Nevertheless, on all Candida reference
panels the amplification efficiencies were reliable (E%= 1.85–
1.94). It must be also noted, that the standard deviations
(mean SD: ±0.12 °C) of the Tm data measured on reference
panels proved to be low even in bright concentration ranges.
Here we demonstrated that when appropriate DNA
samples are available (OD260/2801.82–1.97 and gDNA
concentration of 1–10 ng/μl), CanTub-simplex PCR
assay identifies the seven most frequent pathogenic
Candida species. CanTub-simplex PCR based applica-
tions used in parallel with morphotyping may offer bet-
ter resolution of the species level identification.
This method is technically not demanding and pro-
vides clear, easily traceable protocols on three different
real-time platforms. Single locus primer pair is used so
the method can be easily multiplexed with exogenous or
endogenous TaqMan internal control assays. Here we
also demonstrated that the adaptation of DNA based ap-
plications used in tandem with morphological examina-
tions in clinical diagnostic laboratories can offer better
resolution of species within the genus.
Conclusion
CanTub-simplex PCR targeting the beta-tubulin genes
proved to be sensitive and accurate on all platforms (P1 –
P3) tested here, and has the potential to identify seven
clinically relevant Candida species (C. albicans, C. glabrata,
C. parapsilosis, C. tropicalis, C. krusei, C. guilliermondii, C.
dubliniensis) by using the seven, pre-defined melting clusters
without using reference controls. These features make this
CanTub-simplex PCR advantageous for use as a first-pass
diagnostic adjunct in microbiology laboratories on blood cul-
ture bottles or for direct whole blood testing by making the
patient follow-up more achievable.
Additional files
Additional file 1: Table S1. Intra-, and inter-assay coefficient of variation
of the CanTub-simplex PCR on Candida reference panels. Representation
of the technical duplicates of the Tm data with mean and ± SD measured
on Candida EDTA-WB reference panels at every dilution in a 6-log range.
Intra-assay coefficient of variation was estimated for the particular gDNA
panels on separarte plates (% C.V.-s of Candida ref-panel_1–7) even as for
the plates in a whole (% C.V.-s of ref-plate_1–3). Inter-assay coefficient of
variation was estimated for the CanTub-simplex PCR for the reference
samples of all panels at every dilution in a 6-log range between three
plates finally, grand mean of the sample coefficient of variation (grand %
C.V. on ref-plates) was calculated. (DOCX 37 kb)
Additional file 2: Table S2. Intra-assay coefficient of variation of the
CanTub-simplex PCR on 38 Candida clinical strains via EDTA-WB Candida
clinical panel. Tm data of Candida clinical strains were grouped according
to panels (clin-panel_1–7) and Tm mean was calculated with ±SD.
Coefficient of variation (% C.V.) was calculated for every species. Finally,
intra- and inter-assay consistencies were calculated. (DOCX 21 kb)
Additional file 3: Figure S3. CanTub HRM primer alignment results
using BLAST algorithm. a) Primer positioning in the Candida albicans
beta-tubulin gene with an amplicon size of 203 basepairs. b) Primer
positioning in the Candida dubliniensis beta-tubulin gene with an
amplicon size of 202 basepairs. c) Primer positioning in the Candida
tropicalis beta-tubulin gene with an amplicon size of 204 basepairs. d)
Primer positioning in the Candida glabrata chromosome K with an
amplicon size of 204 basepairs. (DOCX 38 kb)
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